Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin plus toripalimab with or followed by chemotherapy as neoadjuvant therapy for HR-negative, HER2-low breast cancer
CTR20231476Phase 2Active
- Sponsor
- RemeGen
- Start
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin, toripalimab in breast cancer, sponsored by RemeGen. Started Jul 2023; status: active.
02
Drugs
disitamab vedotintoripalimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20231476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231476.